Antiphospholipid syndrome primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Antiphospholipid syndrome}}
{{Antiphospholipid syndrome}}
{{CMG}} {{AE}}
{{CMG}} {{AE}}{{FT}}
 
==Overview==
==Overview==


==Primary Prevention==
==Primary Prevention==
 
In addition to anticoagulation, attention should be paid to minimizing the contribution of reversible risk factors for recurrent thrombosis. During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis
[[Randomized controlled trial]]s have addressed the secondary prevention of thromboses. These trials include APLASA<ref name="pmid17599766">{{cite journal| author=Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L et al.| title=Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. | journal=Arthritis Rheum | year= 2007 | volume= 56 | issue= 7 | pages= 2382-91 | pmid=17599766 | doi=10.1002/art.22663 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17599766  }} </ref>,
[[Randomized controlled trial]]s have addressed the secondary prevention of thromboses. These trials include APLASA<ref name="pmid17599766">{{cite journal| author=Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L et al.| title=Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. | journal=Arthritis Rheum | year= 2007 | volume= 56 | issue= 7 | pages= 2382-91 | pmid=17599766 | doi=10.1002/art.22663 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17599766  }} </ref>,



Revision as of 20:14, 4 April 2018

Antiphospholipid syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Antiphospholipid syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Antiphospholipid syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Antiphospholipid syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Antiphospholipid syndrome primary prevention

CDC on Antiphospholipid syndrome primary prevention

Antiphospholipid syndrome primary prevention in the news

Blogs on Antiphospholipid syndrome primary prevention

Directions to Hospitals Treating Antiphospholipid syndrome

Risk calculators and risk factors for Antiphospholipid syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

Primary Prevention

In addition to anticoagulation, attention should be paid to minimizing the contribution of reversible risk factors for recurrent thrombosis. During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis Randomized controlled trials have addressed the secondary prevention of thromboses. These trials include APLASA[1],

References

  1. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L; et al. (2007). "Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals". Arthritis Rheum. 56 (7): 2382–91. doi:10.1002/art.22663. PMID 17599766.

Template:WH Template:WS